|
|
Abstract
Antibody response to measles, mumps, rubella re-vaccination in HIV-infected children with immune recovery after highly active antiretroviral therapy
Aurpibul L.1, Puthanakit T.1, Sirisanthana T.1, Sirisanthana V.2
Objectives: To evaluate the efficacy and safety of Measles-Mumps-Rubella (MMR) re-vaccination in HIV-infected children with immune recovery after HAART.
Methods: Inclusion criteria were (1) HIV-infected children aged > 5 years with (2) nadir CD4 lymphocyte percentage < 15, (3) immune recovery, defined as CD4 lymphocyte percentage >15 for at least 3 months after receiving HAART, and (4) anti-measles IgG antibody < 320 mIU/ml. Each child received 1 dose of MMR vaccine and antibodies were measured at 4 and 24 weeks after vaccination. Protective antibodies were defined as: anti-measles IgG > 320 mIU/ml, anti-mumps IgG > 1:500, and anti-rubella IgG >10 IU/ml.
Results: There were 51 participants. The median age was 10.2 years (SD 2.5). Prior to re-vaccination none had protective antibody to measles, 11 (20%) had antibody to mumps, and 28 (55%) had antibody to rubella. At 4 weeks after re-vaccination 46 (90.2%) had protective antibody to measles. Twenty nine of 40 children (72.5%) who had no protective antibody to mumps and all 23 children (100%) who had no protective antibody to rubella seroconverted. The prevalence of protective antibodies to measles, mumps and rubella at 24 weeks after re-vaccination were 79.6%, 61.2%, and 93.9 % respectively. There were no serious adverse reactions attributable to revaccination.
Conclusions: The majority of HIV-infected children with immune recovery after HAART can develop protective antibodies after MMR re-vaccination. Re-vaccination in this population should be considered to ensure individual immunity and limit the spread of preventable disease.
4th IAS Conference on HIV Pathogenesis, Treatment and Prevention
Abstract no.
TUPEB139
Suggested Citation
"AurpibulL., et al.
Antibody response to measles, mumps, rubella re-vaccination in HIV-infected children with immune recovery after highly active antiretroviral therapy.
Poster exhibition:
4th IAS Conference on HIV Pathogenesis, Treatment and Prevention:
Abstract no.
TUPEB139"
|
|
|